EUR 17.51 For Business Accounts Only

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA
Allena Pharmaceuticals

Allena Pharmaceuticals is a late-stage, clinical biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company's main product candidate, reloxaliase, is an oral enzyme therapeutic that it is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease (CKD) and other serious kidney disease. The company's second product candidate, ALLN-346, is being developed for patients with hyperuricemia and moderate to severe CKD.

ValuEngine Inc
ValuEngine Inc

​ValuEngine Rating and Forecast Reports provide the most comprehensive and useful report available. ValuEngine's three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. ValuEngine provides coverage of over 5300 US stocks (which includes over 800 ADRs), all of which are updated daily after US market close.


ResearchPool Subscriptions

Get the most out of your insights

Get in touch